SVRA - Savara Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.4600
-0.1600 (-6.11%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.6200
Open2.6500
Bid2.4500 x 38500
Ask2.4500 x 3000
Day's Range2.4200 - 2.7297
52 Week Range2.4200 - 14.0600
Volume3,081,713
Avg. Volume482,942
Market Cap92.794M
Beta (3Y Monthly)1.95
PE Ratio (TTM)N/A
EPS (TTM)-1.3490
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.33
Trade prices are not sourced from all markets
  • Business Wire3 days ago

    Savara to Present at the JMP Securities Life Sciences Conference

    Savara Inc. , an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, and Chief Operating Officer, Taneli Jouhikainen, will present at the JMP Securities Life Sciences Conference on Wednesday, June 19, 2019 at 11:30 a.m.

  • TheStreet.com3 days ago

    Savara Plunges After Lung Disease Drug Fails Phase 3 Trial

    were crumbling Thursday, falling more than 75% after the company announced that its lung disease treatment candidate Molgradex failed its Phase 3 study. "Disappointingly, with the placebo effect stronger than anticipated, the study did not meet its primary endpoint," said Rob Neville, Savara's chief executive officer. The company said that was meeting with the Food and Drug Administration and the European Medicines Agency to discuss the results of the study and to determine its next course of action.

  • Here's Why Savara Pharmaceuticals Collapsed Today
    Motley Fool3 days ago

    Here's Why Savara Pharmaceuticals Collapsed Today

    Investors just received some bad news about the company's lead drug candidate.

  • Savara Plunges on Failure of Late-Stage Study on Molgradex
    Zacks3 days ago

    Savara Plunges on Failure of Late-Stage Study on Molgradex

    Savara's (SVRA) lead pipeline candidate, Molgradex, fails to meet primary endpoint in a phase III study evaluating it in a rare autoimmune lung disorder.

  • TheStreet.com4 days ago

    Savara Shares Slammed on Failed Phase 3 Drug Study

    crumpled in after-hours trading Wednesday after the company said a phase 3 trial of its Molgradex drug treatment for a rare lung disease had failed to meet its test goals. "Disappointingly, with the placebo effect stronger than anticipated, the study did not meet its primary endpoint," said Rob Neville, Savara's chief executive officer.

  • MarketWatch4 days ago

    Savara stock plummets 75% after drug study fails to hit target

    Shares in Savara Inc. , which is seeking to address rare lung diseases, dropped 75% in after-hours trading Wednesday, when the drug company announced that a study failed to hit its target. Savara said a phase 3 study of core pipeline drug Molgradex, which seeks to treat Autoimmune Alveolar Pulmonary Proteinosis, did not meet its primary endpoint. Secondary endpoints were met, and the company said it is figuring out next steps. "We are preparing to meet with the FDA and EMA to discuss the results from this study and to determine our options to seek approval based on the current data, and potentially conduct an additional study incorporating the learnings," Chief Executive Rob Neville said in a statement. Shares were halted ahead of the announcement, after closing at $10.57, which gave the company a market cap of nearly $380 million. When shares were reopened for late trading, the price immediately fell to less than $2.40.

  • Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP)
    Business Wire4 days ago

    Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP)

    Savara Inc. (SVRA), an orphan lung disease company, today announced top line data from IMPALA, a pivotal Phase 3 clinical study evaluating Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of aPAP. An average A-aDO2 improvement of 12.1 mmHg was observed in the continuous dosing arm, compared to an average A-aDO2 improvement of 8.8 mmHg in the placebo arm. With an estimated 4.6 mmHg treatment difference (p=0.17), the study did not meet its primary endpoint.

  • Implied Volatility Surging for Savara (SVRA) Stock Options
    Zacks6 days ago

    Implied Volatility Surging for Savara (SVRA) Stock Options

    Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.

  • Savara Inc. (SVRA) Q1 2019 Earnings Call Transcript
    Motley Foollast month

    Savara Inc. (SVRA) Q1 2019 Earnings Call Transcript

    SVRA earnings call for the period ending March 31, 2019.

  • Savara Inc. (NASDAQ:SVRA) Is Expected To Breakeven
    Simply Wall St.last month

    Savara Inc. (NASDAQ:SVRA) Is Expected To Breakeven

    Savara Inc.'s (NASDAQ:SVRA): Savara Inc. operates as an orphan lung disease company. The US$427m market-cap posted a...

  • Savara Inc (SVRA) Upgraded to Buy: Here's Why
    Zackslast month

    Savara Inc (SVRA) Upgraded to Buy: Here's Why

    Savara Inc (SVRA) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Business Wirelast month

    Savara Reports First Quarter 2019 Financial Results and Provides Business Update

    Top Line Results from Pivotal Phase 3 IMPALA Study Expected in June 2019

  • Business Wirelast month

    Savara Announces Molgradex Received Fast Track Designation by FDA for Treatment of Autoimmune Pulmonary Alveolar Proteinosis

    Savara Inc. (SVRA), an orphan lung disease company, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). Molgradex, the Company’s lead product candidate, is being investigated in a pivotal Phase 3 study, called IMPALA, for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). Topline results from the study are expected in June 2019.

  • Business Wirelast month

    Savara to Report First Quarter 2019 Financial Results and Provide Business Update

    Savara Inc. , an orphan lung disease company, today announced that the Company will report first quarter 2019 financial results and provide a business update on Thursday, May 9, 2019.

  • ACCESSWIRE2 months ago

    Savara to Present at the H.C. Wainwright Global Life Sciences Conference in London

    AUSTIN, TX / ACCESSWIRE / April 2, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that Rob Neville, Chief Executive Officer, will present at the H.C. Wainwright Global ...

  • ACCESSWIRE2 months ago

    Savara Initiates Phase 2a Clinical Study of Molgradex for the Treatment of NTM Lung Infection in People Living with Cystic Fibrosis

    AUSTIN, TX / ACCESSWIRE / April 1, 2019 / Savara Inc. (SVRA), an orphan lung disease company, today announced the initiation of ENCORE, a Phase 2a clinical study evaluating its lead product candidate, Molgradex, for the treatment of nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis (CF). Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) and is also currently in Phase 2a development for NTM in non-CF patients and in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). "People living with CF who have chronic NTM lung infection are in need of improved treatment options to complement current antibiotic regimens," said Rob Neville, Chief Executive Officer.

  • Savara Inc. (SVRA) Q4 2018 Earnings Conference Call Transcript
    Motley Fool3 months ago

    Savara Inc. (SVRA) Q4 2018 Earnings Conference Call Transcript

    SVRA earnings call for the period ending December 31, 2018.

  • ACCESSWIRE3 months ago

    Savara Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Business Update

    AUSTIN, TX / ACCESSWIRE / March 13, 2018 / Savara Inc. (SVRA), an orphan lung disease company, today reported financial results for the fourth quarter and full year ending December 31, 2018 and provided a business update. ''With the approaching data read-out from our pivotal IMPALA study, we enter 2019 with confidence,'' said Rob Neville, Chief Executive Officer, Savara. ''We've started key commercial preparation activities to support a potential launch as we believe Molgradex could transform the standard-of-care for a debilitating disease with no approved therapies.

  • Did Savara Inc. (NASDAQ:SVRA) Insiders Buy Up More Shares?
    Simply Wall St.3 months ago

    Did Savara Inc. (NASDAQ:SVRA) Insiders Buy Up More Shares?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examplesRead More...

  • ACCESSWIRE3 months ago

    Savara To Report Q4/Year-End 2018 Financial Results And Business Update On March 13, 2019

    AUSTIN, TX / ACCESSWIRE / March 6, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced it will release its fourth quarter and year-end 2018 financial results on Wednesday, ...

  • ACCESSWIRE3 months ago

    Savara to Present at the 39th Annual Cowen and Company Healthcare Conference

    AUSTIN, TX / ACCESSWIRE / March 4, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, announced today that the company's Chief Executive Officer, Rob Neville, will present at the 39th Annual ...

  • GlobeNewswire4 months ago

    Savara Provides Update on IMPALA and AVAIL Pivotal Clinical Studies

    Savara Inc. (SVRA), an orphan lung disease company, today provided an update on its two pivotal Phase 3 clinical studies, IMPALA and AVAIL. IMPALA is a pivotal Phase 3 clinical study evaluating Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). It is the largest clinical study ever conducted in aPAP, with a total of 139 people across 34 study sites.

  • Could The Savara Inc. (NASDAQ:SVRA) Ownership Structure Tell Us Something Useful?
    Simply Wall St.5 months ago

    Could The Savara Inc. (NASDAQ:SVRA) Ownership Structure Tell Us Something Useful?

    The big shareholder groups in Savara Inc. (NASDAQ:SVRA) have power over the company. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. Read More...

  • Savara, Inc. (SVRA)Hedge Funds Are Snapping Up
    Insider Monkey6 months ago

    Savara, Inc. (SVRA)Hedge Funds Are Snapping Up

    The government requires hedge funds and wealthy investors with over a certain portfolio size to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings level the playing field for ordinary investors. The latest round of 13F filings disclosed the funds’ positions on September […]